

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO COOPERATION AGREEMENT WITH ANDICON
IN RELATION TO ANTI-INFLUENZA DRUG ADC189**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on October 10, 2023, the Group entered into a cooperation agreement (the “**Agreement**”) with Jiaying AnDiCon Biotech Co., Ltd.* (嘉興安諦康生物科技有限公司) (“**AnDiCon**”) in relation to ADC189 (the “**Product**”), an innovative drug. Pursuant to the Agreement, the Group will obtain the exclusive commercialization rights of the Product in China for indications related to influenza (the “**influenza**”). The cooperation will further strengthen the Group’s product portfolio in the anti-infective area.

ABOUT ADC189

ADC189 is a polymerase acidic (PA) protein inhibitor for anti-influenza, by suppressing cap-dependent endonuclease (CEN) of influenza virus. ADC189 can inhibit the replication of influenza virus directly, and suppress both influenza A and B. As indicated in the pre-clinical research, ADC189 demonstrates several benefits, including the absence of central nervous system side effects, no effect of food intake on oral drug absorption and higher safety dose. As compared with oseltamivir, which needs to be taken for five consecutive days, the entire oral dose of ADC189 is merely “one tablet” and is capable of stopping influenza virus replication in 24 hours, having a prospect of bringing great convenience to a large number of patients, including child patients. Currently, phase III clinical trial of ADC189 for treating influenza is progressing well.

ABOUT ANDICON

Led by a number of top domestic scientists and academicians, AnDiCon is a high-tech biomedical company focusing on development and commercialization of new respiratory anti-infective medicines. Relying on the advantages of its DMPK new drug discovery platform, AnDiCon's innovative product pipeline covers the domain of respiratory anti-infection and gynecology, including influenza, respiratory syncytial virus, oral drugs for endometriosis and uterine fibroids.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Company focuses on the therapeutic areas of oncology, nervous system, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "providing today's patients with medicines of the future". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

LISTING RULES IMPLICATIONS

The entering into the Agreement does not constitute a discloseable transaction under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") as none of the applicable percentage ratios (as defined in Rule 14.07 of the Listing Rules) in respect of the transactions contemplated under the Agreement exceeds 5%.

To the best of the knowledge, information and belief, having made all reasonable enquiries by the Directors, AnDiCon and its ultimate beneficial owners are all third parties independent of the Company and its connected persons (as defined under the Listing Rules).

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, October 10, 2023

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.

* *For identification purposes only*